60 Participants Needed

Xenon MRI for Pulmonary Arterial Hypertension

(Jupiter PH Trial)

SW
SA
DP
Overseen ByDavid Ptashnik, MS
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Bastiaan Driehuys
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, if you are in Cohort 2, you must be either treatment naïve or have started treatment within the last 3 months.

What data supports the effectiveness of the treatment 129Xe Hyperpolarized, Hyperpolarized 129Xe, 129Xe MRI/MRS for Pulmonary Arterial Hypertension?

Research shows that hyperpolarized 129Xe MRI can detect early changes in lung function related to pulmonary hypertension in animal models, suggesting it might help monitor the disease and assess treatment response in humans.12345

How is the treatment 129Xe Hyperpolarized MRI different from other treatments for pulmonary arterial hypertension?

129Xe Hyperpolarized MRI is unique because it is a non-invasive imaging technique that allows doctors to see how well the lungs are working by assessing both ventilation (airflow) and gas exchange. Unlike traditional treatments that focus on managing symptoms, this method provides detailed images of lung function, which can help in diagnosing and monitoring the progression of pulmonary arterial hypertension.34567

What is the purpose of this trial?

This trial uses a special MRI scan with a gas to monitor lung function in patients with severe lung disease. It targets those being monitored over time to better understand and track their condition. The MRI technique provides detailed lung function measurements and is well-tolerated, allowing for thorough exploration of lung function.

Research Team

SR

Sudarshan Rajagopal, MD, PhD

Principal Investigator

Duke University

Eligibility Criteria

This trial is for adults aged 18-75 with Pulmonary Hypertension (PH), specifically those who are newly diagnosed or have started treatment within the last three months. Participants must be able to consent and follow the study schedule, and women of childbearing age need a negative pregnancy test before MRI scans. Those awaiting lung transplants can join too, but not if they have severe liver disease, heart issues, active cancer, sickle cell anemia or conditions preventing MRI use.

Inclusion Criteria

Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed)
Willing and able to give informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed)
Women of childbearing potential must have a negative urine pregnancy test before MRI
See 4 more

Exclusion Criteria

Prisoners and pregnant women will not be approached for the study
Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
I have sickle cell anemia.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo 129Xe MRI scans and standard-of-care assessments including labs, echocardiography, and six-minute walk distance

24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment, with 6-month follow-up appointments

5 years

Treatment Details

Interventions

  • 129Xe Hyperpolarized
Trial Overview The trial is testing how a type of imaging called Xenon 129 Magnetic Resonance Imaging (MRI) can show changes in lung function and blood flow in patients with different types of Pulmonary Hypertension. It aims to understand how these images change with disease progression or after starting treatment.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: following pulmonary arterial hypertension subjectsExperimental Treatment1 Intervention
Following pulmonary arterial hypertension subjects upto 24 months
Group II: end-stage pulmonary hypertension .Experimental Treatment1 Intervention
subjects with end-stage PH that currently on the waitlist for lung transplant

129Xe Hyperpolarized is already approved in United States for the following indications:

🇺🇸
Approved in United States as Hyperpolarized 129Xe for:
  • Pulmonary hypertension (investigational)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Bastiaan Driehuys

Lead Sponsor

Trials
15
Recruited
1,100+

Findings from Research

Hyperpolarized (HP) (129)Xe MRI effectively identified significant pulmonary vascular disease (PVD) in two patients who had normal ventilation but decreased gas transfer, despite inconclusive results from other imaging methods.
The technique shows promise for diagnosing PVD and monitoring treatment responses, but further research is needed to establish its sensitivity and specificity.
Abnormalities in hyperpolarized (129)Xe magnetic resonance imaging and spectroscopy in two patients with pulmonary vascular disease.Dahhan, T., Kaushik, SS., He, M., et al.[2023]
The study introduces a new method for delivering hyperpolarized (129)Xe gas directly into the arterial blood of live rats using an extracorporeal circuit, allowing for continuous infusion and improved imaging capabilities.
This technique enables high-resolution, 3D MRI of lung ventilation and perfusion, facilitating detailed studies of the ventilation-perfusion ratio and potentially expanding the use of (129)Xe for functional imaging in other body areas.
In vivo MR imaging of pulmonary perfusion and gas exchange in rats via continuous extracorporeal infusion of hyperpolarized 129Xe.Cleveland, ZI., Möller, HE., Hedlund, LW., et al.[2021]
This study is the first to use hyperpolarized 129Xe MRI to non-invasively assess pulmonary hypertension in a monocrotaline rat model, showing reduced gas exchange early in the disease and changes in tissue uptake later on.
The imaging results correlated well with histological findings, indicating that 129Xe MRI could be a valuable tool for monitoring disease progression and treatment response in pulmonary hypertension without the need for invasive procedures.
Quantitative 129Xe MRI detects early impairment of gas-exchange in a rat model of pulmonary hypertension.Virgincar, RS., Nouls, JC., Wang, Z., et al.[2021]

References

Abnormalities in hyperpolarized (129)Xe magnetic resonance imaging and spectroscopy in two patients with pulmonary vascular disease. [2023]
In vivo MR imaging of pulmonary perfusion and gas exchange in rats via continuous extracorporeal infusion of hyperpolarized 129Xe. [2021]
Quantitative 129Xe MRI detects early impairment of gas-exchange in a rat model of pulmonary hypertension. [2021]
Functional airway obstruction observed with hyperpolarized 129 Xenon-MRI. [2022]
Brain Imaging Using Hyperpolarized 129Xe Magnetic Resonance Imaging. [2019]
Development of hyperpolarized noble gas MRI. [2019]
Repeatability of regional pulmonary functional metrics of Hyperpolarized 129 Xe dissolved-phase MRI. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security